CY1108428T1 - Μονοϋδροχλωρικο αλας 1-[3 [3-(4-χλωροφαινυλ) προποξυ] προπυλ] - πιπεριδινης - Google Patents

Μονοϋδροχλωρικο αλας 1-[3 [3-(4-χλωροφαινυλ) προποξυ] προπυλ] - πιπεριδινης

Info

Publication number
CY1108428T1
CY1108428T1 CY20081101174T CY081101174T CY1108428T1 CY 1108428 T1 CY1108428 T1 CY 1108428T1 CY 20081101174 T CY20081101174 T CY 20081101174T CY 081101174 T CY081101174 T CY 081101174T CY 1108428 T1 CY1108428 T1 CY 1108428T1
Authority
CY
Cyprus
Prior art keywords
chlorophenyl
propoxy
propyl
monohydrochloride salt
piperidine monohydrochloride
Prior art date
Application number
CY20081101174T
Other languages
Greek (el)
English (en)
Inventor
Manuel M Raga
Juan Sallares
Marta Guerrero
Antonio Guglietta
Jean-Michel Arrang
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Xavier Ligneau
Walter Schunack
Charon Robin Ganellin
Holger Stark
Original Assignee
Bioprojet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34938687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108428(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet filed Critical Bioprojet
Publication of CY1108428T1 publication Critical patent/CY1108428T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
CY20081101174T 2005-02-10 2008-10-21 Μονοϋδροχλωρικο αλας 1-[3 [3-(4-χλωροφαινυλ) προποξυ] προπυλ] - πιπεριδινης CY1108428T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05100942A EP1690858B1 (en) 2005-02-10 2005-02-10 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
EP06708050A EP1846384B1 (en) 2005-02-10 2006-02-06 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine

Publications (1)

Publication Number Publication Date
CY1108428T1 true CY1108428T1 (el) 2014-04-09

Family

ID=34938687

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101174T CY1108428T1 (el) 2005-02-10 2008-10-21 Μονοϋδροχλωρικο αλας 1-[3 [3-(4-χλωροφαινυλ) προποξυ] προπυλ] - πιπεριδινης

Country Status (22)

Country Link
US (2) US8207197B2 (enExample)
EP (2) EP1690858B1 (enExample)
JP (1) JP5072604B2 (enExample)
KR (1) KR101344271B1 (enExample)
CN (1) CN101155793B (enExample)
AR (1) AR054734A1 (enExample)
AT (2) ATE391716T1 (enExample)
CA (1) CA2597016C (enExample)
CY (1) CY1108428T1 (enExample)
DE (2) DE602005005941D1 (enExample)
DK (1) DK1846384T3 (enExample)
ES (1) ES2309948T3 (enExample)
HR (1) HRP20080446T3 (enExample)
ME (1) ME01103B (enExample)
MX (1) MX2007009574A (enExample)
PL (1) PL1846384T3 (enExample)
PT (1) PT1846384E (enExample)
RS (1) RS50624B (enExample)
SI (1) SI1846384T1 (enExample)
TW (1) TWI393711B (enExample)
UY (1) UY29369A1 (enExample)
WO (1) WO2006084833A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
AU2010214101A1 (en) 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
KR20120035183A (ko) 2009-06-10 2012-04-13 선오비온 파마슈티컬스 인코포레이티드 히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법
JP2013504580A (ja) 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッド ヒスタミンh3インバースアゴニストおよびアンタゴニストとその使用方法
WO2014199935A1 (ja) * 2013-06-10 2014-12-18 株式会社エム・エス・エス 小胞体ストレスシグナルを抑制することによる,薬剤の副作用としての体重増加や肥満を防止するために用いられる肥満防止剤
CN103435575A (zh) * 2013-08-06 2013-12-11 中国人民解放军军事医学科学院毒物药物研究所 1-( 3-( 3-( 4-氯苯基)丙氧基)丙基)哌啶盐酸盐的制备方法
CN104447620B (zh) * 2014-11-28 2016-05-04 瑞阳制药有限公司 1-[3-[3-(4-氯苯基)丙氧基]丙基]-哌啶盐酸盐的制备方法
EP3239138A1 (en) 2016-04-25 2017-11-01 Sandoz Ag Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
WO2020092604A1 (en) * 2018-10-30 2020-05-07 Concert Pharmaceuticals, Inc. Deuterated pitolisant
IT201900013941A1 (it) 2019-08-05 2021-02-05 Procos Spa PROCESSO PER LA SINTESI DI PITOLISANT HCl
CN110804026B (zh) * 2019-11-18 2022-04-01 苏州永健生物医药有限公司 1- (3- (3-(4-氯苯基)丙氧基)丙基)哌啶盐酸盐的合成方法
US11945788B2 (en) 2021-06-07 2024-04-02 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
US11623920B2 (en) 2021-06-07 2023-04-11 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
US20250059145A1 (en) * 2021-12-29 2025-02-20 Biophore India Pharmaceuticals Pvt. Ltd. Solid forms of 1-{3-[3-(4-chlorophenyl) propoxy] propyl} piperidine hydrochloride and process for the preparation thereof
US20250281475A1 (en) * 2022-05-04 2025-09-11 Msn Laboratories Private Limited, R & D Center A pharmaceutical composition of pitolisant hydrochloride and their process for the preparation
WO2024084379A1 (en) * 2022-10-17 2024-04-25 Biophore India Pharmaceuticals Pvt. Ltd A NOVEL PROCESS FOR THE PREPARATION OF AMORPHOUS SOLID DISPERSION OF 1-{3-[3-(4-CHLOROPHENYL) PROPOXY] PROPYL} PIPERIDINE, HYDROCHLORIDE WITH HYDROXYPROPYL BETA-CYCLODEXTRIN (HPβCD)
EP4374854A1 (en) * 2022-11-28 2024-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical mixture comprising amorphous pitolisant
JP2026511788A (ja) 2023-03-31 2026-04-14 ビオプロジェ・ファルマ ピトリサント塩酸塩の多形形態
EP4681704A1 (en) 2024-07-18 2026-01-21 BIOPROJET Pharma New formulations of pitolisant
CN122374013A (zh) 2023-10-16 2026-07-10 生物计划制药公司 替洛利生的新制剂和使用方法
EP4732903A1 (en) 2024-10-28 2026-04-29 BIOPROJET Pharma Co-crystals of pitolisant hydrochloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications

Also Published As

Publication number Publication date
EP1690858A1 (en) 2006-08-16
TWI393711B (zh) 2013-04-21
CA2597016A1 (en) 2006-08-17
CN101155793A (zh) 2008-04-02
US8354430B2 (en) 2013-01-15
PL1846384T3 (pl) 2009-01-30
RS50624B (sr) 2010-06-30
JP2008530050A (ja) 2008-08-07
HRP20080446T3 (en) 2008-10-31
UY29369A1 (es) 2006-05-31
SI1846384T1 (sl) 2008-12-31
ES2309948T3 (es) 2008-12-16
DK1846384T3 (da) 2008-11-17
KR20070101381A (ko) 2007-10-16
WO2006084833A1 (en) 2006-08-17
JP5072604B2 (ja) 2012-11-14
MX2007009574A (es) 2007-09-25
AR054734A1 (es) 2007-07-11
TW200639157A (en) 2006-11-16
US8207197B2 (en) 2012-06-26
CA2597016C (en) 2013-01-15
EP1846384A1 (en) 2007-10-24
PT1846384E (pt) 2008-10-21
DE602006001938D1 (de) 2008-09-04
EP1690858B1 (en) 2008-04-09
ME01103B (me) 2013-03-20
US20120289546A1 (en) 2012-11-15
ATE402154T1 (de) 2008-08-15
US20080221162A1 (en) 2008-09-11
ATE391716T1 (de) 2008-04-15
CN101155793B (zh) 2015-05-20
EP1846384B1 (en) 2008-07-23
KR101344271B1 (ko) 2013-12-26
DE602005005941D1 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
CY2020002I1 (el) Μυκητοκτονος συνθεση η οποια περιεχει ενα παραγωγο οξινου αμιδιου
TW200639157A (en) New salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
AR057467A1 (es) Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas
AR054846A1 (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4- piridin-3-il-pirimidin-2- ilamino)-benzamida
NZ594597A (en) Substituted piperidines as ccr3 antagonists
ATE522140T1 (de) Mikrobizide zusammensetzung
MA28999B1 (fr) Compositions destinees a lutter contre un ou plusieurs pathogenes
CY1114662T1 (el) Ημιφουμαρικο αλας του 1-[4-[1-(4-κυκλοεξυλο-3-τριφθορομεθυλο-βενζυλοξυιμινο)-αιθυλο]-2-αιθυλο-βενζυλο]-αζετιδινο-3-καρβοξυλικου οξεος
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
IL192024A0 (en) 3,5-substituted piperidine compounds as renin inhibitors
CY1106857T1 (el) Βενζαμιδια 4-(αμινομεθυλ)-πιπεριδινης ως 5ht4-ανταγωνιστες
PE20071184A1 (es) Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo
EP1933702A4 (en) LEAD SERIES
ATE413388T1 (de) Muskarin antagonisten
CY1109956T1 (el) Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη
CY1107141T1 (el) Μεθοδος για την παρασκευη της 1-(2s,3s)-2-βενζυδρυλ-ν-(5-τριτ.-βουτυλ-2-μεθοξυβενζυλ)κινουκλιδιν-3-αμινης
CY1108321T1 (el) Καινοφανη παραγωγα δικαρβοξυλικου οξεος
NO20070089L (no) DPP-IV inhibitorer
ATE479681T1 (de) Substituierte piperidine
DE602004015610D1 (de) 3-fluoro-piperidine als nmda/nr2b antagonisten
UA90130C2 (ru) Аморфный лерканидипина гидрохлорид и фармацевтическая композиция на его основе
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
DE60138771D1 (de) In der 4-stellung substituierte 5,6-dihydro-4h-pyrroloä1,2-aü ä1,4ü benzodiazepine als fungizide
MA28793B1 (fr) Oxazolidinones contenant des oxindoles, servant d'agents antibactériens